Latest Publications

Share:

EU publishes summary of recent competition enforcement in the pharmaceutical sector and promises to continue policy of proactive...

The European Commission (EC) has published its latest report on competition enforcement in medicines and medical products. Key takeaways are that: EU and Member State authorities imposed multiple material antitrust...more

European Commission sanctions first ever pharmaceuticals cartel and scores victory in pay-for-delay appeal

The European Commission (EC) has fined five pharmaceutical companies a total of EUR13.4 million for participating in a cartel concerning N-Butylbromide Scopolamine/Hyoscine (SNBB) – an active pharmaceutical ingredient (API)...more

ΑG opines that all of Servier’s pay-for-delay deals were restrictions of competition by object

On 14 July 2022, Advocate General (AG) Kokott delivered her much awaited (non-binding) Opinions in Cases C-176/19 P, Commission v Servier and Others and C-201/19 P, Servier and Others v Commission. ...more

Compulsory licensing for expensive medicines – new report published in Belgium

On 14 June 2022, the Belgian Health Care Knowledge Centre (KCE), a think-tank funded by the Belgian government, published a report on the compulsory licensing of expensive medicinal products (the Report). ...more

Belgian Competition Authority fines pharmaceutical wholesalers for their participation in a cartel

In February 2022, the Belgian Competition Authority’s (the BCA) prosecution service (Auditoraat/Auditorat) adopted a settlement decision, sanctioning two pharmaceutical wholesalers, Pharma Belgium-Belmedis SA and Febelco CV,...more

Belgian legislator introduces a filing fee for merger control notifications to the Belgian Competition Authority

The Belgian Chamber of Representatives recently approved a draft law transposing EU Directive 2019/1 to empower the competition authorities of the Member States to be more effective enforcers and to ensure the proper...more

EU’s top court clarifies when a patent settlement agreement can infringe EU antitrust rules

The Court of Justice of the EU (ECJ) has for the first time ruled on the issue of settlement agreements involving a value transfer (monetary or otherwise) between the holder of a pharmaceutical patent and generic drug...more

7 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide